Categories AlphaGraphs, Earnings, Industrials
Southwest Airlines beats Q2 earnings estimates but revenues fall short
Southwest Airlines Co. (NYSE: LUV) reported better-than-expected earnings for the second quarter of 2019 but revenues fell short of estimates, sending the stock tumbling 4.7% in premarket hours on Thursday.
Total operating revenues grew 2.9% year-over-year to $5.90 billion but came in shy of forecasts of $5.94 billion. Passenger revenues increased 2.4% to $5.4 billion.
Net income was $741 million, or $1.37 per share, compared with $733 million, or $1.27 per share, in the year-ago period. Analysts had forecast EPS of $1.34.
Unit revenues (RASM) increased 6.8%, driven mainly by a passenger revenue yield increase of 4.2%, and a load factor increase of 1.7 points. Load factor reached an all-time quarterly record of 86.4%. Revenue passenger miles fell 1.7% while available seat miles (ASM) dropped 3.6%.
Total operating expenses rose 3.6% to $4.9 billion. Unit costs (CASM) increased 7.5%. Economic fuel costs were $2.13 per gallon compared to $2.21 per gallon in the year-ago quarter. Fuel efficiency decreased 1.7% year-over-year, due to the removal of the company’s most fuel-efficient aircraft from its schedule as a result of the MAX groundings.
For the third quarter of 2019, Southwest expects RASM to increase 3-5% versus last year. CASM, ex fuel, is expected to rise 9-11%. Available seat miles are expected to decrease 2-3%. Fuel efficiency is expected to decrease 1-2% year-over-year as a result of the MAX groundings. Economic fuel costs are estimated to be $2.05 to $2.15 per gallon.
For the full year of 2019, CASM, excluding fuel and oil expense and profit-sharing expense, is expected to increase 8-10% year-over-year. ASMs are expected to decrease 1-2% year-over-year.
Due to the delay in MAX deliveries, and based on current guidance from Boeing assuming regulatory approval of MAX return to service during the fourth quarter of 2019, Southwest now estimates its 2019 capital expenditures to be in the range of $1.2 billion to $1.3 billion, compared with its previous guidance in the range of $1.9 billion to $2 billion.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on